About

Erik J. Ostrowski joined Akebia Therapeutics in June 2024 as Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer. He previously served as President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer of AVROBIO, Inc. from May 2023 to June 2024, and as its Chief Financial Officer and Treasurer from January 2019 to May 2023. From 2014 to 2018 he was Chief Financial Officer of Summit Therapeutics plc, and from July 2010 to June 2014 he was Vice President of Finance at Organogenesis Inc. Earlier he worked in investment banking, most recently as a director with Leerink Partners LLC, and began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers LLP).

Roles

Akebia Therapeutics, Inc.
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer · Current role
2024–present
AVROBIO, Inc.
President, Interim CEO, Chief Financial Officer and Treasurer · Public biotechnology company; President and Interim CEO from May 2023 to June 2024.
2019-2024
Summit Therapeutics plc
Chief Financial Officer · Public biotechnology company.
2014-2018
Organogenesis Inc.
Vice President of Finance · Biotechnology company.
2010-2014

External Roles

Faron Pharmaceuticals Oy
Board of directors
2022-2024

Fixed Compensation

FY 2025
Salary
$552,919
ComponentAnnual base salary
All other compensation
$16,877
Total compensation
$1,792,361

Performance Compensation

Data from FY 2025

Cash incentive

Annual cash incentive
$223,074
FormNon-Equity Incentive Plan Compensation

Stock awards

Stock awards
$436,576
FormRSUs / PSUs
Option awards
$562,915
FormStock options

Also at Akebia Therapeutics, Inc.

Related

See how VectorShift works for your firm

Request Demo